Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) vs Synthetic Secretin (ChiRhoStim)
An educational, source-based comparison of Rezafungin (Rezzayo) and Synthetic Secretin (ChiRhoStim) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
27-amino-acid peptide used to stimulate pancreatic secretions for diagnosis.
Synthetic human secretin that stimulates pancreatic bicarbonate, fluid secretion, and gastrin release — used diagnostically for pancreatic function, gastrinoma evaluation, and ERCP facilitation.
- Pancreatic function testing
- Gastrinoma (Zollinger-Ellison) diagnosis
- ERCP facilitation
- • FDA-approved.
- • Single diagnostic dose; minimal adverse effects.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Rezafungin (Rezzayo) | ReSTORE trial | Lancet | 2023 | Non-inferior to caspofungin for candidemia/invasive candidiasis. |
| Synthetic Secretin (ChiRhoStim) | Secretin stimulation test for gastrinoma | Gastroenterology | 1989 | Established as gold standard provocative test. |
Side-effect & safety grid
- FDA-approved (2023).
- Infusion reactions and photosensitivity reported.
- FDA-approved.
- Single diagnostic dose; minimal adverse effects.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Rezafungin (Rezzayo) vs Synthetic Secretin (ChiRhoStim) — Key differences
- Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Synthetic Secretin (ChiRhoStim) is Diagnostic · Gastroenterology.
- Primary research focus: Rezafungin (Rezzayo) — candidemia; Synthetic Secretin (ChiRhoStim) — pancreatic function testing.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Diagnostic.